Foghorn therapeutics announces new preclinical data for selective smarca2 inhibitor fhd-909 and selective cbp and ep300 degrader programs at 2025 aacr meeting

- fhd-909 (ly4050784) advancing in an ongoing phase 1 trial in smarca4 (brg1) mutated cancers, with non-small cell lung cancer (nsclc) as the primary target population

FHTX Ratings Summary

FHTX Quant Ranking